Early Data Support Ability of MicroRNA Mimic, MRG-229, to Treat IPF
New preclinical data support MRG-229, an investigative next-generation treatment for idiopathic pulmonary fibrosis (IPF), as safe and effective, miRagen reported. “We believe this body of evidence supports further development of MRG-229 as a potentially differentiated approach for the treatment of IPF,” William S. Marshall, PhD, the company’s president and CEO, said in…